|
Patent landscape, scope, and claims: |
US Patent 12,239,689: Scope, claim architecture, and CNP-controlled-release patent landscape
What is the core claim scope of US 12,239,689?
US 12,239,689 is directed to a method of treating, controlling, or delaying diseases treatable with a C-type natriuretic peptide (CNP) or CNP agonist, using a subcutaneously administered controlled-release CNP agonist (or composition) built from:
- A CNP “ring” moiety D with a specific disulfide-constrained cyclic sequence
- D includes a ring moiety with amino acid sequence SEQ ID NO:96, with a permitted substitution:
- “methionine at position 11…can be substituted with asparagine”
- The ring moiety is between two cysteine residues forming a disulfide bridge
- The CNP moiety within the structure has an amino acid sequence of SEQ ID NO:24, SEQ ID NO:25, or SEQ ID NO:30
- A reversible prodrug linker L1 that is chemically cleavable (non-enzymatic), with long aqueous stability and defined cleavage kinetics
- Cleavable in aqueous buffer at pH 7.4 and 37°C
- Cleavage release half-life: up to six months
- “covalently and reversibly conjugated” to the side chain (or backbone) of the ring moiety D
- L1 contains a defined structural subpart formula (II), with extensive Markush-style coverage over:
- connectivity patterns of -X-, -X1-, -X2-, -X3-
- substituent classes (alkyl, heteroaryls, heterocycles, cycloalkyls)
- optional intramolecular ring closures and fused-ring formation
- A water-soluble carrier moiety Z attached via L2 to the linker
- L1 substituted with L2-Z, with a specific constraint that the “hydrogen marked with the asterisk…is not replaced by -L2-Z”
- L2 is a single bond or spacer
- Z is water-soluble and includes a moiety of formula (a) with a PEG-based polymeric branching architecture
- The claim specifies:
- branching point BPa: N<, CR<, or >C<
- a set by branching type (0 for N< or CR<; 1 for >C<)
- polymer segment choice across C1-50 alkyl / C2-50 alkenyl / C2-50 alkynyl with optional substitutions and interrupts
- Pa′, Pa″ and Pa′″ are independently a polymeric moiety comprising a PEG-based moiety
- polymer length parameters:
- Z is explicitly water-soluble and designed to shape pharmacokinetics and release
- A functional pharmacology filter tied to prodrug activation
The controlled-release conjugate must satisfy two pharmacodynamic requirements:
- Release half-life in buffer:
- “D-H released … by cleavage of the linker with a release half-life of at least 6 hours”
- in aqueous buffer pH 7.4, 37°C, no enzymes
- Suppression of free agonist potency until release:
- the controlled-release CNP agonist has EC50 at least 20-fold higher than EC50 of corresponding D-H
- Disease scope limited to specific CNP-responsive disorders
Claim 1 limits “one or more diseases” to:
- achondroplasia
- hypochondroplasia
- Noonan syndrome
- SHOX deficiency
- Route limitation
- Subcutaneous (s.c.) administration to the mammalian patient
What does this mean in practice?
US 12,239,689 is not a generic CNP delivery claim. It is a highly structured prodrug-polymer conjugate claim where enforceability turns on whether an accused product uses the same:
- cyclic CNP moiety architecture (SEQ ID constraints),
- reversible cleavable linker with non-enzymatic cleavage kinetics,
- PEG-based water-soluble carrier (with defined branching parameters),
- and pharmacology ratios (EC50 shift) consistent with a prodrug release design.
How are claims 1–10 layered to narrow or strengthen the scope?
The dependent claims add further constraints on potency shift, release kinetics, target indication, and polymer molecular weight, plus an alternative polymer formula embodiment.
Claim 1: baseline “method” claim with full structural and functional package
Claim 1 includes all of the following simultaneously:
- s.c. administration
- controlled-release CNP agonist or composition
- specific structure classes:
- D ring moiety SEQ constraints (SEQ ID NO:96 plus methionine 11 to asparagine option; disulfide ring)
- CNP moiety SEQ ID NO:24/25/30
- reversible prodrug linker L1 with aqueous non-enzymatic cleavage up to 6 months
- L1 substituted by L2-Z
- Z includes PEG-based polymer branching with BPa and parameters x (1–16) and y (1–5)
- structural subparts for L1 with formula (II)
- disease limitation: achondroplasia, hypochondroplasia, Noonan syndrome, SHOX deficiency
- pharmacology constraints:
- release half-life ≥ 6 hours (pH 7.4, 37°C, no enzymes)
- EC50 controlled-release at least 20-fold higher than D-H
Claim 2: potency shift strengthened (EC50 ratio)
- Controlled-release CNP agonist EC50 is at least 50-fold higher than D-H.
Claim 3: potency shift strengthened further
- Controlled-release CNP agonist EC50 is at least 100-fold higher than D-H.
Claim 4: release kinetics strengthened
- D-H release half-life ≥ 24 hours.
Claim 5: release kinetics further strengthened
- D-H release half-life ≥ 168 hours (7 days).
Claim 6: disease narrowed to achondroplasia
- disease = achondroplasia.
Claim 7: narrows CNP moiety sequence
- CNP moiety = SEQ ID NO:24.
Claim 8: polymer molecular weight floor (branched)
- polymer is branched
- MW ≥ 20 kDa.
Claim 9: polymer molecular weight floor increased
- polymer is branched
- MW ≥ 30 kDa.
Claim 10: additional polymer structural formula embodiment
- polymer is “of formula (g)” with:
- substituted Z architecture
- definitions of -Sg-, -Sg′-, -Sg″- and continued PEG-based branching elements:
- “Pa′, Pa″ and Pa′″ are independently a polymeric moiety comprising a PEG-based moiety”
- Claim 10 expands the Markush-based formula coverage for the polymer portion (still within the same overall architecture of the claim family).
What is the claim “center of gravity” for infringement or licensing?
In enforcement terms, the tightest hooks are:
- The reversible prodrug linker L1 with non-enzymatic aqueous cleavage
- The claim sets release half-life minima (≥ 6 hours; dependent thresholds extend to 24 hours and 168 hours) and also states linker “half-life of up to six months” in aqueous buffer without enzymes.
- The PEG-based water-soluble carrier Z with defined branching parameters
- BPa selection, PEG-based polymeric moieties Pa′/Pa″/Pa′″, and polymer length parameters x and y.
- The EC50 suppression requirement (prodrug potency filter)
- Controlled-release EC50 must be at least 20x, optionally 50x or 100x higher than corresponding D-H.
- Specific CNP cyclic architecture (SEQ-driven)
- SEQ ID NO:96 ring moiety constraints and SEQ ID NO:24/25/30 for the CNP moiety are central. A non-matching CNP peptide sequence likely falls outside.
- Subcutaneous route and disease set
- s.c. and one of the listed indications are both explicit claim limitations.
How broad is the Markush coverage, and where does it narrow?
Broad where:
- L1 structural subparts include extensive choices for:
- link group connectivity patterns (various placements of heteroatoms and unsaturation markers),
- substituent selection over alkyl and heterocycles,
- optional intramolecular ring closures and heterocycle formations,
- multiple optional bond pairings.
Narrow where:
- the architecture of D is sequence-constrained:
- SEQ ID NO:96 ring moiety with disulfide arrangement plus the allowed substitution at position 11.
- the identity of the CNP moiety is constrained to one of three sequence IDs:
- Z is not just “PEG”: it is PEG-based polymeric branching with defined parameters and specified moiety classes.
- functional filters (EC50 ratio, non-enzymatic release half-life) create an additional “technical merit” barrier to design-around.
What does the patent landscape likely look like around CNP prodrugs and controlled-release conjugates in the US?
The landscape in US practice for CNP therapies typically clusters into three strategy buckets:
- CNP agonists / peptide agonists (including natural or modified CNP mimetics)
- CNP stability and half-life extensions (e.g., PEGylation, Fc fusion, polymer conjugation)
- Prodrug and linker systems (controlled cleavage to release active peptide)
US 12,239,689 is squarely in the third bucket: a controlled-release CNP prodrug conjugate with a polymer carrier and explicit non-enzymatic release kinetics in physiological buffer.
Where US 12,239,689 will overlap with likely prior art / competitor claims
Based on claim structure, likely overlap zones for other patents include:
- cyclic CNP moieties and disulfide-constrained ring embodiments;
- non-enzymatic aqueous-cleavable linkers (not relying on proteases);
- PEG-based branching polymer carriers for solubility and PK modulation;
- prodrug designs with measurable EC50 or potency suppression until conversion.
Where it will differentiate
US 12,239,689’s differentiators are not “CNP + prodrug” in general, but the specific combination of:
- SEQ ID constraints for D and the embedded CNP sequences,
- L1/L2/Z architecture with formula-defined linker and PEG branching parameters,
- and strict potency ratio and release half-life constraints.
What is the exploitable IP leverage in licensing or designing around?
For licensing:
- The claim family appears built to support broad commercial coverage across:
- multiple CNP sequence embodiments (24/25/30),
- multiple disease indications within the CNP-responsive set,
- multiple release kinetics and potency suppression targets (dependent claims),
- multiple polymer MW embodiments (≥ 20 kDa, ≥ 30 kDa),
- and multiple polymer structural formula embodiments (formula (g)).
For designing around:
- A design is most vulnerable if it matches the trifecta:
- cyclic CNP architecture sequence requirements,
- L1 cleavable non-enzymatic linker kinetics and prodrug EC50 suppression,
- PEG branched carrier Z parameters.
A design-around is most plausible by breaking at least one of these anchors:
- altering the CNP moiety sequence set outside SEQ ID NO:24/25/30,
- using an enzymatically cleaved linker or non-matching non-enzymatic release kinetics,
- deploying a non-PEG or non-branching / non-parameterized carrier architecture so that Z falls outside formula (a) and branching definitions,
- or eliminating EC50 suppression relative to D-H (prodrug that is not potency-suppressed).
Key claim-to-commercial parameters (for diligence)
The claims define several measurable “targets” that map directly to development and CMC testing:
| Claim element |
Concrete measurable parameter in claims |
| Non-enzymatic release |
release half-life ≥ 6 hours (claim 1); ≥ 24 hours (claim 4); ≥ 168 hours (claim 5) in buffer pH 7.4 at 37°C without enzymes |
| Prodrug potency suppression |
controlled-release EC50 at least 20x (claim 1), 50x (claim 2), 100x (claim 3) vs corresponding D-H |
| Route |
subcutaneous administration |
| Indications |
achondroplasia, hypochondroplasia, Noonan syndrome, SHOX deficiency (claim 1) |
| Polymer architecture |
branched polymer, PEG-based moieties Pa′/Pa″/Pa′″, x = 1–16, y = 1–5 (claim 1); MW thresholds ≥ 20 kDa and ≥ 30 kDa (claims 8–9) |
| Sequence identity constraints |
D ring moiety SEQ ID NO:96 with optional Met11→Asn; CNP moiety SEQ ID NO:24/25/30 (claims 1, 7) |
What is the scope of “method” protection versus composition protection?
Claim 1 is framed as a method of treating/controlling/delaying, and it ties infringement to:
- administering the controlled-release CNP agonist (or composition) subcutaneously,
- to a patient with one of the specified diseases,
- using a molecule defined by formulas and functional EC50/release criteria.
In practice, this means that product-level substitution may still implicate the method claim if the product composition administered satisfies the molecular definitions and testing thresholds recited in the claim.
Key Takeaways
- US 12,239,689 claims a subcutaneous prodrug controlled-release CNP agonist conjugate with a defined cyclic CNP architecture (SEQ ID NO:96 ring moiety with disulfide constraint; CNP moiety SEQ ID NO:24/25/30) and a reversible, non-enzymatic aqueous-cleavable linker.
- The invention’s enforceable center is the combined presence of: (i) PEG-based branched carrier Z with specified parameters, (ii) non-enzymatic release half-life thresholds, and (iii) EC50 suppression relative to the released D-H.
- Dependent claims tighten coverage to higher EC50 ratios (50x, 100x), longer release (24 hours; 168 hours), specific indication (achondroplasia), specific CNP moiety sequence (SEQ ID NO:24), and polymer MW thresholds (≥ 20 kDa; ≥ 30 kDa), while claim 10 adds a specific polymer formula embodiment.
FAQs
1) Does US 12,239,689 cover enzymatic cleavage linkers?
No. The claim specifies non-enzymatic cleavage behavior in aqueous buffer at pH 7.4 and 37°C, with defined release half-life requirements.
2) Is the patent limited to one CNP sequence?
No. Claim 1 allows the CNP moiety to be one of SEQ ID NO:24, SEQ ID NO:25, or SEQ ID NO:30; claim 7 narrows to SEQ ID NO:24.
3) What role do EC50 ratios play in claim scope?
They are a functional requirement: the controlled-release conjugate must show EC50 at least 20-fold higher than the corresponding released D-H (with dependent claims at 50-fold and 100-fold).
4) Can a product fall within the claim without being PEG-based?
It is highly constrained: Z includes PEG-based polymeric moieties (Pa′/Pa″/Pa′″) and defined branching parameters in the polymer moiety definitions.
5) What diseases are explicitly covered?
Claim 1 lists achondroplasia, hypochondroplasia, Noonan syndrome, and SHOX deficiency, and dependent claim 6 narrows to achondroplasia.
References
[1] Claim text provided in user prompt: US Drug Patent 12,239,689 (claims 1–10).
More… ↓
⤷ Start Trial
|
